 Avalon GloboCare Corp NASDAQ: AVCO is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor Natural Killer CAR-NK cell therapies. Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors. 